Content about Joe Papa

February 4, 2013
Perrigo: Already-strong private label growth will get additional boost from Rx-to-OTC switch

Perrigo chairman, CEO and president Joe Papa shared with analysts that private label OTCs are trending strong and that growth will be sustained going forward with the number of projected Rx-to-OTCs on the horizon.

ALLEGAN, Mich. — Perrigo chairman, CEO and president Joe Papa on Friday shared with analysts that private label OTCs are trending strong and that growth will be sustained going forward with the number of projected Rx-to-OTCs on the horizon. 

January 15, 2013
Reuters: CVS/pharmacy will stock Tylenol in only half of its stores

CVS/pharmacy has decided to stock Tylenol pain reliever in only half of its stores, according to a Reuters report published Monday.

NEW YORK — CVS/pharmacy has decided to stock Tylenol pain reliever in only half of its stores, according to a Reuters report published Monday. 

According to the report, CVS will stock Tylenol in each market, but not in each store as CVS seeks to plug any out-of-stock holes left behind by the initial recall of Tylenol three years ago and the brand's slow trek back to shelf. 

January 10, 2012
Perrigo forecasts sunny days now and in the future for private-label OTC

Over the past year, store-brand sales of over-the-counter products have helped maintain a slight growth through the sector, and with the number of proposed prescription-to-OTC switches on the horizon, the future looks especially bright, Joe Papa, Perrigo chairman, president and CEO, told attendees of the 30th Annual J.P. Morgan Healthcare Conference held Monday.

NEW YORK — Over the past year, store-brand sales of over-the-counter products have helped maintain a slight growth through the sector, and with the number of proposed prescription-to-OTC switches on the horizon, the future looks especially bright, Joe Papa, Perrigo chairman, president and CEO, told attendees of the 30th Annual J.P. Morgan Healthcare Conference held here Monday.

August 17, 2011
Perrigo 2012 targets: Prevacid 24HR and Align; Lipitor on the horizon?

Perrigo is planning to launch more than 45 new products in fiscal 2012 that will translate into approximately $190 million added to annual Perrigo sales, Perrigo chairman, president and CEO Joe Papa told analysts during the company's fourth-quarter conference call Tuesday.

ALLEGAN, Mich. — Perrigo is planning to launch more than 45 new products in fiscal 2012 that will translate into approximately $190 million added to annual Perrigo sales, Perrigo chairman, president and CEO Joe Papa told analysts during the company's fourth-quarter conference call Tuesday.

And while none of these new over-the-counter private-label products will help reduce cholesterol levels, Papa did set the stage for a future store-brand equivalent to Pfizer's blockbuster statin Lipitor.